(from Tech Journal South, Jan 18, 2010)
RESEARCH TRIANGLE PARK, NC – Four startup companies will present at the CED’s STREAK showcase Thursday, Jan. 28 at the CED’s headquarters in the RTP.
The CED, formerly the Council for Entrepreneurial Development will showcase the four companies to an audience of investors, entrepreneurs, service providers, local government agencies and university representatives.
“These four companies represent some of the most promising entrepreneurial efforts in technology and life sciences from our community,” said Bob Pickens, director of entrepreneurship at CED. “Our panel’s insights provided needed guidance in steering each company toward successful entry into their respective markets.”
Presenting companies are:
– Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics. The company’s initial program focuses on inhibiting RecA, a key enzyme in bacterial DNA repair as well as in the development and transmission of antibiotic resistance. Prototype RecA inhibitors potentiate the killing of a wide variety of pathogenic bacteria by a broad range of bactericidal antibiotics. President and Chief Scientific Officer Dr. Scott Singleton will present.
– Axial Exchange is a Raleigh-based clinical information transmitter. Via last-mile open-source appliance, the company enables health care systems of all types to share data to solve key business problems. An Axial subscription gives clients 360-degree interoperability via the Axial Appliance, which stays up-to-date with the latest software, connectors and policy content via the Axial Network. Founder and CEO Joanne Rohde will present.
– PlotWatt offers a Web-based service to provide residential electricity users with customized recommendations for drastically reducing their home’s electric bills. Easily installable monitors feed data from the consumer’s circuit breaker to a data processing center. Proprietary algorithms are then applied to the data to translate total energy consumption into appliance-level cost and actionable recommendations. Founder and CEO Luke Fishback will present.
– Vascular Pharmaceuticals is focused on the development and commercialization of novel therapeutic products for the treatment of cardiovascular and metabolic complications related to diabetes. Founded in 2005 by Dr. David R. Clemmons, Chief of the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill, the company has three active research programs focused on diabetic atherosclerosis, retinopathy and obesity. CEO Richard Shea will present.